A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Inclusion Criteria:

- Signed written informed consent

- Diagnosis of RCC with clear-cell or predominant clear-cell histology

- Subjects with non-metastatic disease (M0) fulfilling any of the following combinations
of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging
version 2010 and Fuhrman nuclear grading.

- pT2, G3 or G4, N0; or,

- pT3, G any, N0; or,

- pT4, G any, N0; or,

- pT any, G any, N1

- Fulfill all of the following criteria of disease-free status at baseline:

- Had complete gross surgical resection of all RCC via radical or partial
nephrectomy using either open or laparoscopic technique.

- Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual
tumor lesions as confirmed centrally by an independent radiologist.

- Received no prior adjuvant or neo-adjuvant treatment for RCC

- Recovered from nephrectomy: any surgery related toxicities should be reduced to ≤
grade 1 per NCI Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)

- Karnofsky performance scale (KPS) of ≥ 80

- Adequate organ system function

Exclusion Criteria:

- History of another malignancy. Exception: Subjects who have had another malignancy and
have been disease-free for 5 years, or subjects with a history of completely resected
non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including, but not limited to:

- Active peptic ulcer disease

- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
gastrointestinal conditions with increased risk of perforation

- History of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to beginning study treatment

- Active diarrhea of any grade

- Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product including, but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel

- History of human immunodeficiency virus (HIV) infection

- History of active hepatitis

- Presence of uncontrolled infection.

- History of any one or more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- History of Class III or IV congestive heart failure, as defined by the New York Heart
Association Classification of Congestive Heart Failure

- History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

- Corrected QT interval (QTc) > 480 milliseconds (msec)

- Poorly controlled hypertension, defined as systolic blood pressure (SBP) of ≥140 mmHg
or diastolic blood pressure (DBP) of ≥ 90mmHg.

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
study entry. Blood pressure (BP) must be re-assessed on two occasions that are separated by
a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values
from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the
study (see Section 7.6.2 for instruction on blood pressure measurement and obtaining mean
blood pressure values).

- Evidence of active bleeding or bleeding diathesis

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
could interfere with subject's safety, provision of informed consent, or compliance to
study procedures

- Unable or unwilling to discontinue use of prohibited medications for at least 14 days
or five half-lives of a drug (whichever is longer) prior to the first dose of study
treatment and for the duration of the study.

- Concurrent therapy given to treat cancer including treatment with an investigational
agent or concurrent participation in another clinical trial involving anti-cancer
investigational drug.

- Administration of an investigational drug within 30 days or 5 half-lives, whichever is
longer, preceding the first dose of study treatment.

- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib or excipients that in the opinion of the investigator
contraindicates their participation.

- Prior or current use of systemic anti-VEGF inhibitors, cytokines (e.g. interferon,
interleukin 2).